Q3 EPS Estimate for ArriVent BioPharma Increased by Analyst

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – HC Wainwright lifted their Q3 2026 EPS estimates for shares of ArriVent BioPharma in a report issued on Thursday, October 8th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.02) per share for the quarter, up from their prior estimate of ($1.04). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.06) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($0.98) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($1.02) EPS and FY2027 earnings at ($3.97) EPS.

A number of other research analysts also recently weighed in on AVBP. Wall Street Zen downgraded ArriVent BioPharma from a “sell” rating to a “strong sell” rating in a report on Saturday. JonesTrading lowered their target price on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research note on Tuesday, September 22nd. Citigroup dropped their price target on ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.44.

ArriVent BioPharma Stock Performance

ArriVent BioPharma stock opened at $16.46 on Monday. The stock’s 50 day simple moving average is $28.50 and its two-hundred day simple moving average is $29.27. The stock has a market cap of $811.61 million, a price-to-earnings ratio of -4.55 and a beta of 1.34. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06).

Institutional Investors Weigh In On ArriVent BioPharma

Several hedge funds have recently bought and sold shares of AVBP. Quantbot Technologies LP purchased a new position in ArriVent BioPharma during the second quarter valued at $59,000. Jupiter Topco LLC bought a new stake in ArriVent BioPharma in the second quarter worth $226,000. Arizona State Retirement System bought a new stake in ArriVent BioPharma in the second quarter worth $233,000. Glenmede Trust Co. NA purchased a new stake in shares of ArriVent BioPharma in the first quarter worth $209,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of ArriVent BioPharma in the first quarter worth $209,000. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.